Skip to main content
. 2015 Oct 2;6(33):35107–35115. doi: 10.18632/oncotarget.5959

Table 3. Adverse event in our study compared with the FLAGS study.

S-1plus cisplatin 5-FU plus cisplatin
Our result (%) FLAGS Study (%) Our result (%) FLAGS Study (%)
All Grade 3/4 All Grade 3/4 All Grade 3/4 All Grade 3/4
Neutropenia 68.6 36.4 28.6 18.6 55.9 13.6 47.2 40.0
Anemia 80.2 25.6 44.0 15.7 72.0 11.9 46.1 19.3
Leucopenia 71.9 17.6 17.5 7.3 62.7 5.9 23.0 13.8
Thrombocytopenia 44.6 14.1 17.7 5.4 26.3 4.2 22.8 8.5
Diarrhea 24.0 5.8 29.2 4.8 17.8 1.7 38.4 4.5
Vomiting 43.0 4.1 48.0 7.9 42.4 5.1 55.3 9.6
Nausea 50.4 3.3 61.6 7.5 60.2 4.2 67.3 9.6
Anorexia 38.0 2.5 31.5 6.0 41.5 3.4 34.8 5.5
Constipation 20.7 0 / / 22.0 0.9 / /
Abdominal pain 15.7 1.7 25.1 7.3 5.9 0 22.4 5.3
Fatigue 21.5 0 39.3 12.3 22.0 0 39.4 13.2
Abnormal pigmentation 10.7 0 / / 1.7 0 / /
Hypokalemia 4.1 0 6.9 3.6 4.2 0.9 16.7 10.8
Dehydration / / 12.1 4.8 / / 15.6 7.5
Weight loss 0.8 0 28.4 4.0 0 0 32.3 6.1
Stomatitis 3.3 0.8 6.3 1.3 6.8 0.9 30.1 13.6